License and Asset Purchase Agreements - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended					3 Months Ended		6 Months Ended
	Aug. 31, 2021	Jan. 31, 2021	Oct. 31, 2020	Nov. 30, 2019	Aug. 31, 2019	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Feb. 28, 2019
License and Asset Purchase Agreements [Line Items]
Licensing agreement milestone fees					$ 2,000
License agreement milestone payments paid				$ 75,000	2,000
License agreement, additional milestone payment due					102,000
Cost of product sold						$ 18,921	$ 12,687	$ 33,637	$ 23,097
Accrued Sales Based Trademark and Royalties						17,125		17,125		$ 16,396
Upon Acceptance by FDA of Pitolisant's
License and Asset Purchase Agreements [Line Items]
License agreement, milestone payment due											$ 50,000
Upon FDA Approval of WAKIX
License and Asset Purchase Agreements [Line Items]
License agreement, milestone payment due					77,000
Licensing agreement milestone fees					$ 2,000
License agreement milestone payments paid		$ 100,000	$ 2,000
Sales-based, Trademark and Tiered Royalties
License and Asset Purchase Agreements [Line Items]
Cost of product sold						$ 17,125	$ 11,812	30,797	$ 21,359
All Countries Excluding Greater China | HBS-102 | Asset Purchase Agreement with ConSynance Therapeutics [Member]
License and Asset Purchase Agreements [Line Items]
Consideration transferred	$ 3,500
Payment for intellectual property upon preclinical milestones	1,750
Payment for intellectual property upon developmental milestones	19,000
Payment for intellectual property upon sales milestones	110,000
Payment for intellectual property upon regulatory milestones	$ 44,000
Bioprojet | United States
License and Asset Purchase Agreements [Line Items]
Amount of Aggregate Net Sales Attaining								500,000
Bioprojet | Attaining $500,000 Aggregate Net Sales | United States | Upon FDA Approval of WAKIX
License and Asset Purchase Agreements [Line Items]
Final payment paid								$ 40,000